Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Association of CD31 and p53 With Survival of Ovarian Cancer Patients

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. The Role of Local Therapy in Multi-focal Epithelioid Haemangioendothelioma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Annexin A2 and S100A10 as Candidate Prognostic Markers in Epithelial Ovarian Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The Influence of Cyst Emptying, Lymph Node Resection and Chemotherapy on Survival in Stage IA and IC1 Epithelial Ovarian Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Hypoxia-regulated MicroRNAs in Gastroesophageal Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Ovarian removal at or after benign hysterectomy and breast cancer: a nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND/AIM: New markers for ovarian cancer are needed. This study aimed to examine the expression of tumour cell p53 and endothelial cell CD31 proteins and correlate them to clinicopathological factors.

PATIENTS AND METHODS: Expression of proteins was immunohistochemically assessed using tissue sections from 585-599 ovarian cancer patients from the Danish MALOVA study.

RESULTS: High CD31 expression was found in poorly differentiated tumours (p=0.0006), and high p53 expression was found in poorly differentiated cancers (p<0.0001), high clinical stage (p<0.0001), non-radical surgery (p<0.0001) and high serum CA-125 values (p<0.0001). CD31 expression showed no prognostic survival value, but high hazard ratios were found for patients with high p53 expression (HR=2.313, p<0.0001). An interaction was found between p53 and stage of cancer, suggesting a prognostic impact of p53 in low-stage, but not in advanced-stage cancer.

CONCLUSION: More than 5% of p53 tissue expression may predict shorter survival of ovarian cancer patients and may be useful for predicting the risk of disease progression in low-stage patients following primary surgery. CD31 has no strong prognostic value.

OriginalsprogEngelsk
TidsskriftAnticancer Research
Vol/bind39
Udgave nummer2
Sider (fra-til)567-576
Antal sider10
ISSN0250-7005
DOI
StatusUdgivet - feb. 2019

Bibliografisk note

Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

ID: 58605882